Literature DB >> 34278542

Global molecular epidemiology of carbapenem-resistant Escherichia coli (2002-2017).

Brian D Johnston1,2, Paul Thuras1,2, Stephen B Porter1, Melissa Anacker3, Brittany VonBank3, Paula Snippes Vagnone3, Medora Witwer3, Mariana Castanheira4, James R Johnson5,6.   

Abstract

The emergence of carbapenem-resistant (CR) Escherichia coli obliges an assessment of such strains' molecular epidemiology. Accordingly, we characterized in detail a globally distributed collection of CR E. coli isolates, then explored for associations between geographical origin and bacterial traits, and between different bacterial traits. We used established PCR-based assays and broth microdilution MIC determinations to characterize 343 global CR (i.e., non-susceptible to ≥ 1 carbapenem) extraintestinal E. coli isolates (2002-2017) for diverse molecular traits-including phylogroups, sequence types (STs), beta-lactamase genes, and 51 virulence genes-and susceptibility to 12 relevant antimicrobial agents. The study population was tremendously diverse according to all assessed variables. Nonetheless, certain geographically aligned, unifying themes emerged. These included an association of an Asia/West Pacific origin with non-B2/D/F phylogroups and STs, lower molecularly inferred virulence, more extensive resistance, and specific resistance genes (notably, metallo-beta-lactamases). Likewise, U.S. isolates from the central region, vs. other regions, were more virulent-appearing and more often from phylogroup B2 and ST131, but less extensively resistant and more often carbapenemase-gene negative. The global CR E. coli population is highly diverse according to multiple characteristics and varies significantly by geographical region. This predictably will pose challenges for prevention and management, and obliges ongoing surveillance.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Antimicrobial resistance; Beta lactamases; CMY-2; CTX-M; Carbapenem resistance; Escherichia coli; Fluoroquinolone resistance; KPC; Molecular epidemiology; NDM; OXA-48; ST131; Sequence types

Year:  2021        PMID: 34278542     DOI: 10.1007/s10096-021-04310-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  1 in total

1.  Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.

Authors:  Brian D Johnston; Paul Thuras; Stephen B Porter; Melissa Anacker; Brittany VonBank; Paula Snippes Vagnone; Medora Witwer; Mariana Castanheira; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

  1 in total
  3 in total

1.  Intestinal Persistence of Colonizing Escherichia coli Strains, Especially ST131-H30, in Relation to Bacterial and Host Factors.

Authors:  James R Johnson; Connie Clabots; Stephen B Porter; Tricia Bender; Brian D Johnston; Paul Thuras
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

2.  Carbapenemase-Producing Extraintestinal Pathogenic Escherichia coli From Argentina: Clonal Diversity and Predominance of Hyperepidemic Clones CC10 and CC131.

Authors:  María Belén Sanz; Denise De Belder; J M de Mendieta; Diego Faccone; Tomás Poklepovich; Celeste Lucero; Melina Rapoport; Josefina Campos; Ezequiel Tuduri; Mathew O Saavedra; Claudia Van der Ploeg; Ariel Rogé; Fernando Pasteran; Alejandra Corso; Adriana E Rosato; Sonia A Gomez
Journal:  Front Microbiol       Date:  2022-03-18       Impact factor: 5.640

3.  Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015-2017.

Authors:  Gisele Peirano; Liang Chen; Diego Nobrega; Thomas J Finn; Barry N Kreiswirth; Rebekah DeVinney; Johann D D Pitout
Journal:  Emerg Infect Dis       Date:  2022-05       Impact factor: 16.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.